Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence

Wefers, Christina; Lambert, Laurens J.; Torensma, Ruurd; Hato, Stanleyson V.

doi:10.1016/j.ygyno.2015.02.019

Cited by 33 publications

(22 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumour-associated antigen (TAA)-specific T cells can infiltrate the tumour microenvironment [25], and these T cells can also be induced via tumour vaccines [26]. However, the immune system often fails to eliminate cancer cells.…”

Section: Introductionmentioning

confidence: 99%

Ovarian cancer stem cells promote tumour immune privilege and invasion via CCL5 and regulatory T cells

You

et al. 2017

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryEmerging evidence indicates a link between the increased proportion of regulatory T cells (T regs ) and reduced survival in patients who have been diagnosed with cancer. Cancer stem cells (CSCs) have been indicated to play a vital role in tumour initiation, drug resistance and recurrence. However, the relationship between T regs and CSCs remains largely unknown. Here, we sorted out ovarian cancer stem-like side population (SP) cells and CD133 1 cells to investigate the influence of ovarian CSCs on T regs . Among the various immune-related molecules that we assessed, C-C motif chemokine ligand 5 (CCL5) was the most elevated in ovarian CSCs relative to that in the non-CSCs. The expression of its receptor, C-C motif chemokine receptor 5 (CCR5), was also increased on the surface of T regs in ovarian cancer patients. This receptor-ligand expression profile indicated that ovarian CSCs recruit T regs via CCL5-CCR5 interactions. We further assessed the expression of interleukin (IL)-10 in T regs cultured with different cancer cells. For the first time, to our knowledge, our findings describe the relationship between ovarian CSCs and T regs , and demonstrated that these two cell populations co-operate to promote tumour immune tolerance and enhance tumour progression.

show abstract

Section: Introductionmentioning

confidence: 99%

Ovarian cancer stem cells promote tumour immune privilege and invasion via CCL5 and regulatory T cells

You

et al. 2017

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…Ovarian cancer is the most prevalent gynecological malignancy in the world, and its incidence is increasing in both developed and developing countries [1,2]. Despite several medical advancements in the treatment of ovarian cancer, the survival rate has not improved significantly [3].…”

Section: Introductionmentioning

confidence: 99%

Circulating Insulin-Like Growth Factor-1 Level and Ovarian Cancer Risk

Zhang²,

Zheng³

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Insulin-like growth factor-1 (IGF-1) has an important role in cells' proliferation, differentiation and apoptosis, and it may be involved in carcinogenesis. Several epidemiological studies assessed the association between circulating IGF-1 level and ovarian cancer risk, but there was still no conclusive finding. Methods: A meta-analysis of published studies was performed to assess the association between circulating IGF-1 level and ovarian cancer risk. The summary odds ratio (OR) with 95% confidence interval (95%CI) was calculated through meta-analysis to evaluate the strength of the association. Results: Five eligible studies were included into the meta-analysis, which involved a total of 2,028 cases of ovarian cancer and 4,625 controls. Meta-analysis of total 5 studies showed that high circulating IGF-1 level was correlated with decreased risk of ovarian cancer (OR = 0.84, 95%CI 0.74-0.97, P = 0.013). After adjusting for heterogeneity, high circulating IGF-1 level was still correlated with decreased risk of ovarian cancer (OR = 0.83, 95%CI 0.72-0.95, P = 0.007). Subgroup analysis by age showed that circulating IGF-1 level was not correlated with ovarian cancer risk in women both less than 55 years and more than 55 years. However, after adjusting for heterogeneity, high circulating IGF-1 level was correlated with decreased ovarian cancer risk in women less than 55 years (OR = 0.82, 95%CI 0.72-0.94, P = 0.004). Conclusion: Our meta-analysis suggests that high circulating IGF-1 level may be correlated with decreased ovarian cancer risk, especially in women less than 55 years. More studies are needed to further assess the association between circulating IGF-1 level and ovarian cancer risk in the future.

show abstract

“…Whereas advanced ovarian cancer is generally responsive to conventional combinations of primary cytoreductive surgery and paclitaxel-platinum chemotherapy initially, most ovarian cancer patients will inevitably relapse with metastasis, recurrence, and drug resistance [2, 3]. Although deadly, ovarian cancer is one of the more chemosensitive solid malignancies.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological and Prognostic Significance of Cancer Stem Cell Markers in Ovarian Cancer Patients: Evidence from 52 Studies

Tao

Huang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Relevant markers of cancer stem cells (CSCs) may serve as commonly used biomarkers of ovarian cancer (OC). However, their actual clinicopathological and prognostic significance remains inconclusive. Thus, we conducted a meta-analysis to quantitatively evaluate the association between the expression of CSC-relevant markers (ALDH1, CD117, CD133, and CD44) and OC. Methods: We used an odds ratio (OR) and a hazard ratio (HR) with a 95% confidence interval (CI) to estimate the effects by analyzing 52 studies from a literature search. Heterogeneity and sensitivity were evaluated, as well. Publication bias was assessed using funnel plots and Egger tests. Results: ALDH1 expression was statistically associated with FIGO stage (OR=1.872, 95%CI=1.14-3.076, P=0.013) and lymph invasion (OR=2.78, 95%CI=1.08-7.152, P=0.034). CD117 expression was significantly associated with FIGO stage (OR=2.01, 95%CI=1.35-2.98, P=0.001). CD133 expression was correlated with FIGO stage (OR=3.410, 95%CI=2.196-5.294, P< 0.001) and differentiation grade (OR=2.672, 95%CI=1.354-5.272, P=0.005). CD44s was related to chemotherapy resistance (OR=3.218, 95%CI=1.148-9.016, P=0.026). Furthermore, overexpression of ALDH1 (HR=1.494, 95%CI=1.207-1.849, P< 0.001), CD117 (HR=1.395, 95%CI=1.025-1.898, P=0.034) or CD44s (HR=1.725, 95%CI=1.135-2.623, P=0.011) was associated with poor OS. Further, overexpression of both ALDH1 (HR=1.524, 95%CI=1.158-2.007, P=0.003) and CD44s (HR=2.12, 95%CI=1.692-2.657, P< 0.001) was correlated with worse DFS. Conclusion: CSC markers are useful predictive or prognostic biomarkers for OC in clinical assessments. Combined detection of CSC marker expression may be a powerful tool for prognostic predictions in clinical practice for patients with OC.

show abstract

Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence

Cited by 33 publications

References 70 publications

Ovarian cancer stem cells promote tumour immune privilege and invasion via CCL5 and regulatory T cells

Ovarian cancer stem cells promote tumour immune privilege and invasion via CCL5 and regulatory T cells

Circulating Insulin-Like Growth Factor-1 Level and Ovarian Cancer Risk

Clinicopathological and Prognostic Significance of Cancer Stem Cell Markers in Ovarian Cancer Patients: Evidence from 52 Studies

Contact Info

Product

Resources

About